Qi Liang

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

Jianyou Shi, Hong Zhang, Xinwei Yang, 2022, Frontiers in Pharmacology.

Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.

Rongsheng Tong, Jianyou Shi, Minghan Sun, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

SPARC in hematologic malignancies and novel technique for hematological disease with its abnormal expression.

Tao Jiang, Zhongyuan Han, Chi Liu, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research.

Rongsheng Tong, Jianyou Shi, Qiaodan Zhou, 2021, European journal of medicinal chemistry.

Targeting matrix metalloproteases: A promising strategy for herbal medicines to treat rheumatoid arthritis

Wei Peng, Yong-liang Huang, Qing Zhang, 2022, Frontiers in Immunology.

HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode.

Rongsheng Tong, Jianyou Shi, Zhongliang Jiang, 2022, Bioorganic chemistry.

Recent research and development of DYRK1A inhibitors

Rongsheng Tong, Lan Bai, Jianyou Shi, 2021, Chinese Chemical Letters.

ROCK inhibitor: Focus on recent updates

Lin Wang, Wen Li, Jianyou Shi, 2023, Chinese Chemical Letters.

Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases

Yonghe Hu, Jianyou Shi, Lei Zhong, 2023, European Journal of Medicinal Chemistry.